One Case of Anaphylaxis Caused by Magnesium Isoglycyrrhizinate Injection

doi:10.19803/j.1672-8629.20240482

Abstract

Abstract: Objective To analyze the etiology and characteristics of anaphylaxis induced by magnesium isoglycyrrhizinate injection so as to provide references for clinical safe use. Methods One case of anaphylaxis caused by intravenous drip of magnesium isoglycyrrhizinate injection was analyzed. The adverse reactions of magnesium isoglycyrrhizinate injection and the pathogenesis of anaphylaxis were reviewed. Results The chances of anaphylaxis being induced by magnesium isoglycyrrhizinate injection were considered high. After active anti-allergic therapy and symptomatic support therapy, the symptoms of anaphylaxis gradually subsided and improved. Conclusion When magnesium isoglycyrrhizinate injection is used, clinicians ought to be alert to the risk of adverse reactions and severe allergic reactions, especially among patients with a history of allergy, and be ready to take precautions.

Key words: Magnesium Isoglycyrrhizinate, Injection, Allergic Shock, Pharmacovigilance, Adverse Drug Reaction

CLC Number:

R975
R994.11

JIANG Nan, WANG Kun, ZHANG Gangping, XING Ruimin, WANG Haiye. One Case of Anaphylaxis Caused by Magnesium Isoglycyrrhizinate Injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1309-1311.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240482

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I11/1309

References

[1] HAN ZJ, XU MJ, LIU L, et al.Research Progress on Pharmacological Action and Clinical Application of Magnesium Isoglycyrrhizinate[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2023, 31(3): 238-242.
[2] LU LH.Analysis on the Clinical Efficacy of Magnesium Isoglycyrrhizinate for the Treatment of Chronic Hepatitis B[J]. Modern Diagnosis and Treatment(现代诊断与治疗), 2022, 33(24): 3688-3690.
[3] SUN YH, DING N, HUANG JY, et al.A Case of Anaphylactic Shock Caused by Intravenous Infusion of Magnesium Isoglycyrrhizinate[J]. Pharmaceutical Care and Research(药学服务与研究), 2022, 22(1): 88-89.
[4] LUO J, WU Y, CAO LZ, et al.A Case of Death Due to Anaphylactic Shock Caused by Intravenous Infusion of Magnesium Isoglycyrrhizinate[J]. China Pharmacist(中国药师), 2015, 18(12): 2129-2130.
[5] WENG JH, XU JH, LI J, et al.A Case of Anaphylactic Shock Caused by Intravenous Infusion of Magnesium Isoglycyrrhizinate Injection.[J]. Guangdong Medical Journal(广东医学), 2014, 35(6): 808-808.
[6] HUA S, PANG LF, LI LH, et al.A case of Anaphylactic Shock Caused by Magnesium Isoglycyrrhizinate Injection: Report and Analysis[J]. Central South Pharmacy(中南药学), 2019, 17(6): 968-970.
[7] LIANG XY, ZHANG XY, KE W, et al.A Case of Adverse Drug Reactions Caused by Intravenous Infusion of Magnesium Isoglycyrrhizinate[J]. China Pharmacist(中国药师), 2017, 20(1): 135-136.
[8] LUO J, LIU GP, HUANG SW, et al.Research Progress in Predicting Anaphylactic Response of Cephalosporins by Skin Test[J]. Anti-Infection Pharmacy(抗感染药学), 2024, 21(2): 113-117.
[9] LI M, SUN H, ZHANG JS.Update in The Clinical Research of Drug Induced Anaphylactic Shock[J]. Journal of Practical Shock(实用休克杂志中英文), 2021, 5(1): 1-5.
[10] YANG Y, HUANG L, TIAN CC, et al.Magnesium Isoglycyrrhizinate Alleviate Airway Inflammatory Responses in Ovalbumin-Induced Mouse Model of Allergic Asthma[J]. Immunopharmacology and Immunotoxicology, 2022, 44(4): 31.
[11] ZHENG FX, XU YX, LI C, et al.Study on Stability of Magnesium Isoglycyrrhizinate Injection[J]. Modern Chinese Medicine(中国现代中药), 2019, 21(8): 1094-1908.
[12] YANG QT, WU C, LIN XL, et al.Research Progress on Drug Pseudoallergy and Its Mechanisms[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2023, 31(2): 159-163.
[13] GONG JY.Evidence-Based Evaluation of Glycyrrhizic acid Preparations in The Prevention and Treatment of Firstline Anti-Tuberculosis Drug-Induced Liver Injury and Its Mechanism Based on Gut Microbiota[D]. Changsha: Central South University, 2024.
[14] RUAN J, YIN H, YANG RX, et al.Clinical Study Magnesium Isoglycyrrhizinate in The Treatment of HIV/MTB Co-infection Patients with Antituberculosis Drug-induced Liver Injury[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(19): 2001-2005.

[1]	WEI Manli, LYU Linyan, ZHENG Zhiyuan, YIN Jiye, MAI Zhixiong. Preclinical genotoxicity evaluation of xueshuantong injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1014-1018.
[2]	LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua. Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
[3]	WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo. Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
[4]	WU Fan, FU Linjie, ZHU He, XU Mengyan. Signal detection of adverse reaction of endothelin receptor antagonists based on FAERS and JADER database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1056-1063.
[5]	LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan. One case of acute severe pancreatitis caused by pegaspargase and its etiology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077.
[6]	LIU Yi, LIU Xiaoqiang, YAO Xiao, LI Xuantang, GUO Xianhui, GENG Ying, PEI Yusheng. Clinical compatibility of bromhexine injectable preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 884-887.
[7]	SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
[8]	WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
[9]	WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi. 560 cases of adverse drug reaction/event caused by Mailu Shutong pills [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
[10]	ZHAO Jun, DONG li, WANG Yang, LIANG Yu, YANG Xue, LI Enze. Adverse reaction/event reports of esmolol [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 925-930.
[11]	ZHANG Qian, YUN Yuan, HE Lian. Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
[12]	CHAO Ying, ZHANG Xuemei, ZHANG Chengjian, WANG Bei. One case of ureterolith combined with gallstone caused by Ceftriaxone sodium for injection in children [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 943-945.
[13]	GUO Haiyan, HE Bo, YAN Hongli, YANG Xueting. One case of persistent hiccup caused by Wenxin Keli [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 946-948.
[14]	WANG Dan, DONG Duo, TIAN Chunhua. Course of development of pharmocovigilance systems in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
[15]	SHAO Bo, GUO Xiaoxin. Review of pharmacovigilance of traditional Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 741-745.